Cas:859775-23-8 3,4-Dichlorophenylglyoxal hydrate manufacturer & supplier

We serve Chemical Name:3,4-Dichlorophenylglyoxal hydrate CAS:859775-23-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3,4-Dichlorophenylglyoxal hydrate

Chemical Name:3,4-Dichlorophenylglyoxal hydrate
CAS.NO:859775-23-8
Synonyms:3,4-Dichlorophenylglyoxal hydrate;OR1627;(3,4-Dichlorophenyl)(oxo)acetaldehyde hydrate (1:1);2-(3,4-dichlorophenyl)-2-oxoacetaldehyde hydrate;Benzeneacetaldehyde, 3,4-dichloro-α-oxo-, hydrate (1:1)
Molecular Formula:C8H6Cl2O3
Molecular Weight:221.037
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:43.37000
Exact Mass:219.969406
LogP:2.31070

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,4-Dichlorophenylglyoxal hydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzeneacetaldehyde, 3,4-dichloro-α-oxo-, hydrate (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,4-Dichlorophenylglyoxal hydrate Use and application,3,4-Dichlorophenylglyoxal hydrate technical grade,usp/ep/jp grade.


Related News: BetterUp currently works with more than 370 organizations, of which more than 40 have European headquarters. New partners in the region include bp, which will be onboarding employees this month to support the mental fitness and well-being of the company’s teams. 3-chloro-6-(3,5-dimethylpyrazol-1-yl)pyridazine manufacturers Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. Bupivacaine hydrochloride suppliers AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023. 3-Fluorosalicylic acid vendor & factory.